
News|Videos|November 16, 2023
Exploring Treatment Strategies for Lymphoma: CAR T-Cell, Tafasitamab, and Clinical Trials
Author(s)Matthew A. Lunning, DO, FACP
An in-depth examination of relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and tafasitamab, based on clinical trial data and patient eligibility.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
2
Exploring the IO Interface: Bridging Knowledge Gaps in Immunotoxicity Management
3
Medication Burden Linked With Acute Care Use in ARSI-Treated Prostate Cancer
4
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
5









































